Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Remaining repurchase amount Share Repurchase Program, Remaining Authorized, Amount Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Costs in Cash Flow Statement Lease, Cost [Table Text Block] Rights retained Advance Future Royalties, Retained Rights After Annual Sales Threshold Exceeded Advance Future Royalties, Retained Rights After Annual Sales Threshold Exceeded Cover [Abstract] Cover [Abstract] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Directors Director [Member] Schedule of Future Minimum Annual Obligations Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Mutual funds Mutual Fund [Member] Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Number of shares, Restricted stock units expected to vest (in dollars per share) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Commercial sales first exceed $100.0 million Commercial Sales Milestone [Member] Commercial Sales Milestone Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] PD-1 (Jemperli/Dostarlimab) AnaptysBio-generated Anti-PD-1 (Jemperli/Dostarlimab) [Member] AnaptysBio-generated Anti-PD-1 (Jemperli/Dostarlimab) Schedule of Non-cash Stock-based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Pay vs Performance Disclosure [Line Items] Liabilities Related To Sale Of Future Royalties [Line Items] Liabilities Related To Sale Of Future Royalties [Line Items] Liabilities Related To Sale Of Future Royalties Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount By the end of 2026 First Installment [Member] First Installment Preclinical and other unallocated costs Preclinical And Other Unallocated Costs [Member] Preclinical And Other Unallocated Costs Net Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Proceeds from stock options exercised Proceeds from Stock Options Exercised Fair Value Measurements and Available for Sale Investments Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Issued under ESPP (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued Common stock, shares outstanding (in shares) Stockholders' equity, beginning balance (in shares) Stockholders' equity, ending balance (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Shares reserved for future award grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Revenue from Contract with Customer [Abstract] Plan Name [Domain] Plan Name [Domain] Other long-term assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested GSK GlaxoSmithKline [Member] GlaxoSmithKline Total number of shares purchased (in shares) Treasury Stock, Shares, Acquired First MAA approval - first indication First Marketing Authorization Application Approval - First Indication [Member] First Marketing Authorization Application Approval - First Indication Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money market funds Money Market Funds [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities IND clearance from the FDA Clearance Of Investigational New Drug From FDA [Member] Clearance Of Investigational New Drug From FDA [Member] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Reimbursement Reimbursement Payments to Acquire Productive Assets Reimbursement Payments to Acquire Productive Assets Monthly base rate (in dollars per sqft) Rent Per Square Foot Rent Per Square Foot U.S. Treasury Securities US Treasury Securities [Member] Schedule of Performance Shares, Outstanding Activity Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Remaining maturity (in years) Available-for-sale Debt Securities, Remaining Maturity Available-for-sale Debt Securities, Remaining Maturity Office furniture and equipment Office Equipment [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Available-for-sale securities, debt securities Total Fair Value Debt Securities, Available-for-Sale Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Aggregate intrinsic value, options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Compensation Amount Outstanding Recovery Compensation Amount Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Regulatory approval for marketing of the first licensed product in the EU Regulatory Approval For Marketing Of The First Licensed Product In The EU [Member] Regulatory Approval For Marketing Of The First Licensed Product In The EU JEMPERLI Royalty Monetization Agreement JEMPERLI Royalty Monetization Agreement [Member] JEMPERLI Royalty Monetization Agreement Tabular List, Table Tabular List [Table Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Receivables from collaborative partners Receivables, Net, Current Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] CEO Chief Executive Officer [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Accrued expenses Total accrued expenses Accrued Liabilities, Current Options to purchase common stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Filing of the first BLA - second indication Filing of Biologics License Application - Second Indication [Member] Filing of Biologics License Application - Second Indication Asset Acquisition [Axis] Asset Acquisition [Axis] ANB033 ANB033 [Member] ANB033 Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Current assets: Assets, Current [Abstract] First BLA approval - first indication First Biologics License Application Approval - dMMREC [Member] First Biologics License Application Approval - dMMREC Payment for net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Authorized repurchase amount Share Repurchase Program, Authorized, Amount First MAA approval - second indication First Marketing Authorization Application Approval - Second Indication [Member] First Marketing Authorization Application Approval - Second Indication Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Options to purchase common stock Stock Options Share-Based Payment Arrangement, Option [Member] Released (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2026 Lessee, Operating Lease, Liability, to be Paid, Year One License License [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Number of Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Royalty Agreement, Above $2.5 billion Royalty Agreement, Above $2.5 billion [Member] Royalty Agreement, Above $2.5 billion Weighted-average exercise price per share, Stock options exercisable, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Liabilities Related To Sale Of Future Royalties [Table] Liabilities Related To Sale Of Future Royalties [Table] Liabilities Related To Sale Of Future Royalties CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Royalties and milestones, agreement amount to be received Advance Future Royalties, Aggregate Additional Payment Advance Future Royalties, Aggregate Additional Payment Current portion of operating lease liability Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued John Schmid [Member] John Schmid Eric Loumeau [Member] Eric Loumeau Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Gross Unrealized Losses Unrealized losses on available-for-sale (less than) Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Potential future payments Asset Acquisition, Contingent Consideration Arrangements, Range of Outcomes, Value, High Asset Acquisition, Contingent Consideration Arrangements, Range of Outcomes, Value, High Schedule of Repurchase Activity Class of Treasury Stock [Table Text Block] Proceeds from sale of future royalties Proceeds From Advance Future Royalties Proceeds From Advance Future Royalties Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, gross Property, Plant and Equipment, Gross Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Royalties Royalty Agreement [Member] Royalty Agreement Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Weighted-Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Royalties and milestones received Cumulative Repayment Of Advance Future Royalty And Milestones Cumulative Repayment Of Advance Future Royalty And Milestones Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Unrealized (loss) gain on available for sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Royalty Agreement, Above $1. 0 billion Below $1.5 Billion Royalty Agreement, Above $1. 0 billion Below $1.5 Billion [Member] Royalty Agreement, Above $1. 0 billion Below $1.5 Billion Total stockholders’ equity Stockholders' equity, beginning balance Stockholders' equity, ending balance Equity, Attributable to Parent Sagard Sagard Healthcare Royalty Partners, LP [Member] Sagard Healthcare Royalty Partners, LP Collaborative Research and Development Agreements Collaborative Arrangement Disclosure [Text Block] Lease renewal term Lessee, Operating Lease, Renewal Term Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Accrued for repurchases of common stock Accrued Common Stock Repurchased Accrued Common Stock Repurchased Comprehensive gain (loss), net Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Recurring Fair Value, Recurring [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross 12 months or greater, Fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Sale of Stock [Domain] Sale of Stock [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Imsidolimab Imsidolimab [Member] Imsidolimab All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted average remaining contractual term, options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term ASSETS Assets [Abstract] Award equivalent shares Share-based Compensation Arrangement by Share-based Payment Award, Common Share Equivalent Share-based Compensation Arrangement by Share-based Payment Award, Common Share Equivalent Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Milestone revenue recognition Contract with Customer, Timing of Satisfaction of Performance Obligation and Payment Document Type Document Type Exclusive License Agreement Exclusive License Agreement [Member] Exclusive License Agreement Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Segment Revenue, Loss and Significant Expenses Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Average price paid per share (in dollars per share) Shares Acquired, Average Cost Per Share Weighted average remaining contractual term, options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Royalty Agreement, Above $1. 5 billion Below $2.5 Billion Royalty Agreement, Above $1.5 billion Below $2.5 Billion [Member] Royalty Agreement, Above $1.5 billion Below $2.5 Billion Schedule of Royalty Transaction Activity Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Share price (in dollars per share) Shares Issued, Price Per Share Leasehold improvements Leasehold Improvements [Member] Schedule of Weighted Average Assumptions used to Estimate Fair Value Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Title of Individual [Axis] Title and Position [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] FDA regulatory approval for marketing of first licensed product in the USA for the treatment of active flares in GPP FDA Regulatory Approval For Marketing Of First Licensed Product In The USA For The Treatment Of Active Flares In GPP [Member] FDA Regulatory Approval For Marketing Of First Licensed Product In The USA For The Treatment Of Active Flares In GPP Receivables from collaborative partners Increase (Decrease) in Contract with Customer, Asset GlaxoSmithKline Collaboration Collaborative Arrangement [Member] Class of Stock [Line Items] Class of Stock [Line Items] Net sales royalty Commercial sales Net Sales Royalty Threshold Net Sales Royalty Threshold Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in dollars per share) Earnings Per Share, Diluted Title of Individual [Domain] Title and Position [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Amortization of right-of-use assets – operating Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Income taxes paid Income Taxes Paid Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Milestones that may be recognized in the future Milestones Yet To Be Recognized [Member] Milestones Yet To Be Recognized Sale of Future Royalties Sale Of Future Royalties Text Block [Text Block] Sale Of Future Royalties Text Block Centessa Pharmaceuticals (UK) Limited (Centessa) Centessa Pharmaceuticals (UK) Limited (Centessa) [Member] Centessa Pharmaceuticals (UK) Limited (Centessa) Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Other income (expense), net: Nonoperating Income (Expense) [Abstract] Short-term investments Debt Securities, Available-for-Sale, Current Forfeitures and cancellations (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Weighted average period remaining for amortization of unrecognized compensation cost (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Lease Agreement 10770 Wateridge Circle, San Diego, California 92121 [Member] 10770 Wateridge Circle, San Diego, California 92121 Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Total other expense, net Nonoperating Income (Expense) Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Number of additional shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Research and development Research and Development Expense (Excluding Acquired in Process Cost) Number of reportable segments Number of Reportable Segments Total liabilities and stockholders’ equity Liabilities and Equity Number of shares, Restricted stock units expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Jemperli Royalty Monetization Agreement Amendment 1 Jemperli Royalty Monetization Agreement Amendment One [Member] Jemperli Royalty Monetization Agreement Amendment One Subsequent Event Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued compensation and related expenses Employee-related Liabilities, Current Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid in capital Additional Paid in Capital Phase 2 clinical trial initiation Phase 2 Clinical Trial Initiation [Member] Phase 2 Clinical Trial Initiation [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Net share settlement of restricted stock units Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated Other Comprehensive Gain ( Loss) AOCI Attributable to Parent [Member] Name of Property [Domain] Name of Property [Domain] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Agency securities US Government Agencies Debt Securities [Member] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Issuance of common stock from exercises of options and employee stock purchase plan Stock Issued During Period, Value, Options and Employee Stock Purchase Plan Stock Issued During Period, Value, Options and Employee Stock Purchase Plan Open Market Sales Agreement Open Market Sales Agreement [Member] Open Market Sales Agreement Weighted average grant date fair value, beginning balance (in dollars per share) Weighted average grant date fair value, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Reportable Segment Research and Development Segment [Member] Research and Development Segment Commercial and corporate obligations Commercial And Corporate Obligations [Member] Commercial And Corporate Obligations [Member] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Long-term investments Debt Securities, Available-for-Sale, Noncurrent Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Annual increase in number of shares available for issuance percentage Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Schedule of Available-for-sale Investments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Dennis Mulroy [Member] Dennis Mulroy Stock options outstanding, beginning balance (in dollars per share) Stock options outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Zejula revenue prior to the Zejula Royalty Monetization Agreement Zejula Revenue [Member] Zejula Revenue Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Existing drug supply Drug Supply [Member] Drug Supply Stock options outstanding, beginning balance (in shares) Stock options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Schedule of Grant Date Fair Value Assumptions Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Exercise Price Award Exercise Price Accrued research, development and manufacturing expenses Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current First BLA approval - second indication First Biologics License Application Approval - Second Indication [Member] First Biologics License Application Approval - Second Indication Underwriting discounts and commissions and offering expenses Payments Of Stock Issuance Costs And Underwriting Discounts And Commissions Payments Of Stock Issuance Costs And Underwriting Discounts And Commissions Arrangement Duration Trading Arrangement Duration Weighted average remaining contractual term, other than options vested and expected to vest (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Terms Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Terms Stockholders’ equity: Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Less than 12 months, Fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Name of Property [Axis] Name of Property [Axis] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Phase 3 clinical trial initiation - first indication Phase 3 Clinical Trial Initiation - First Indication [Member] Phase 3 Clinical Trial Initiation - First Indication Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Royalties agreement, maximum annual royalty payout capacity Advance Future Royalties, Annual Sales Threshold Advance Future Royalties, Annual Sales Threshold Aggregate intrinsic value, restricted stock units expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value All Individuals All Individuals [Member] Settlement agreement rate Advance Future Royalties, Minimum Global Net Sales, Rate Advance Future Royalties, Minimum Global Net Sales, Rate Milestones that may be recognized in the future Revenue Recognition, Milestone Method, Contingent Revenue Recognition, Milestone Method, Contingent Zejula Royalty Monetization Agreement Zejula Royalty Monetization Agreement [Member] Zejula Royalty Monetization Agreement PEO PEO [Member] Name Trading Arrangement, Individual Name Other income (expense), net Other Nonoperating Income (Expense) Principal repayment of liability for sale of future royalties Royalty and milestone payments to Sagard Repayment Of Advance Future Royalty And Milestones Repayment Of Advance Future Royalty And Milestones Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Royalty percent on net sales Net Sales Royalty, Percent Net Sales Royalty, Percent Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Non-cash interest expense for the sale of future royalties Non-cash interest expense Non-cash interest expense recognized Non-cash interest expense Noncash Advance Future Royalties, Interest Expense Noncash Advance Future Royalties, Interest Expense Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Investments at fair value Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Accretion/amortization of investments, net Unrealized Gain (Loss) on Investments Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Schedule of Time-based Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Stock-based compensation APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Measure: Measure [Axis] Filing of the first MAA - second indication Filing of MMA - Second Indication [Member] Filing of MMA - Second Indication Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Deferred income Deferred Income Transaction costs expensed Collaborative Arrangement Costs Collaborative Arrangement Costs Entity Emerging Growth Company Entity Emerging Growth Company Issuance of common stock from exercises of options and employee stock purchase plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options And Employee Stock Purchase Plan Share-based Compensation Arrangement by Share-based Payment Award, Options And Employee Stock Purchase Plan Advance Future Royalties, Payment [Axis] Advance Future Royalties, Payment [Axis] Advance Future Royalties, Payment Amounts accrued for repurchases of common stock Repurchase of Common Stock Incurred But Not Yet Paid Repurchase of Common Stock Incurred But Not Yet Paid Underwritings Underwriting Agreement [Member] Underwriting Agreement Segment Reporting [Abstract] Net share settlement of restricted stock units (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Entity Central Index Key Entity Central Index Key Phase 3 clinical trial initiation - second indication Phase 3 clinical Trial Initiation - Second Indication [Member] Phase 3 clinical Trial Initiation - Second Indication [Member] General and administrative General and Administrative Expense [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-cash interest expense capitalized Noncash Interest Expense, Negative Amortization Noncash Interest Expense, Negative Amortization Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Stockholders' Equity Equity [Text Block] Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Advance Future Royalties, Payment [Domain] Advance Future Royalties, Payment [Domain] Advance Future Royalties, Payment [Domain] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Segment Reporting Segment Reporting Disclosure [Text Block] Jemperli Royalty Monetization Agreement Jemperli Royalty Monetization Agreement [Member] Jemperli Royalty Monetization Agreement Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Number of shares issuable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Shares Issuable Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Shares Issuable Title Trading Arrangement, Individual Title Increase in annual rent percentage Annual Rent Increase, Percent Annual Rent Increase, Percent Statement [Table] Statement [Table] ANB032 ANB032 [Member] ANB032 Measurement Frequency [Domain] Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] City Area Code City Area Code Transaction costs incurred Asset Acquisition, Consideration Transferred, Transaction Cost Current liabilities: Liabilities, Current [Abstract] Equity Incentive Plan, 2017 Equity Incentive Plan, 2017 [Member] Equity Incentive Plan, 2017 [Member] Interest portion of repayment for sale of future royalties Interest Paid, Excluding Capitalized Interest, Operating Activities Liability related to sale of future royalties Advance Future Royalties, Liability, Noncurrent Advance Future Royalties, Liability, Noncurrent Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Cash payment Payments to Acquire Productive Assets Quoted Market Prices for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Repurchase and retirements of common stock Payments for Repurchase of Common Stock Shares subject to options, exercisable, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Liabilities Related To Sale Of Future Royalties [Roll Forward] Liabilities Related To Sale Of Future Royalties [Roll Forward] Liabilities Related To Sale Of Future Royalties Deferred income Increase (Decrease) In Deferred income Increase (Decrease) In Deferred income Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Weighted average grant date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Repurchases and retirements of common stock Stock Repurchased and Retired During Period, Value 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Net loss per common share: Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Repurchases and retirements of common stock (in shares) Stock Repurchased and Retired During Period, Shares Filing of the first MAA - first indication Filing of MMA - First Indication [Member] Filing of MMA - First Indication Security deposit Security Deposit Forfeitures and cancellations (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Employee Stock Purchase Plan, 2017 Employee Stock Purchase Plan, 2017 [Member] Employee Stock Purchase Plan, 2017 [Member] General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Lease liability Total Operating Lease, Liability Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount PSU Performance Shares [Member] Filing of the first BLA - first indication Filing of Biologics License Application - First Indication [Member] Filing of Biologics License Application - First Indication Interest income Interest Income, Other Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Subsequent Events [Abstract] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Lease termination term Lessee, Operating Lease, Expiration Period Lessee, Operating Lease, Expiration Period Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Basis of Consolidation Consolidation, Policy [Policy Text Block] Net of proceeds Advance Future Royalties, Liability, Noncurrent, Net Advance Future Royalties, Liability, Noncurrent, Net Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Common stock, $0.001 par value, 500,000 shares authorized, 30,388 shares and 30,473 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively Common Stock, Value, Issued Royalty Agreement, Up To $1.0 billion Royalty Agreement, Up To $1. 0 billion [Member] Royalty Agreement, Up To $1. 0 billion Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value DRI Healthcare Trust DRI Healthcare Trust [Member] DRI Healthcare Trust Second commercial sales milestone Second Commercial Sales Milestone [Member] Second Commercial Sales Milestone Aggregate offering of (up to) Sale of Stock, Authorized Aggregate Offering, Maximum Sale of Stock, Authorized Aggregate Offering, Maximum Vanda Vanda Pharmaceuticals Inc. [Member] Vanda Pharmaceuticals Inc. Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Forfeitures and cancellations (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Beginning balance Ending balance Advance Future Royalties, Liabilities Advance Future Royalties, Liabilities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2025 and December 31, 2024, respectively Preferred Stock, Value, Issued Stock awards Share-Based Payment Arrangement [Member] Shares Subject to Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] ESPP Employee Stock [Member] Basic (in dollars per share) Earnings Per Share, Basic Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Daniel Faga [Member] Daniel Faga Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Award expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other Liabilities Disclosure [Abstract] Effective interest rate Advance Future Royalties, Interest Rate, Effective Percentage Advance Future Royalties, Interest Rate, Effective Percentage Fourth commercial sales milestone Fourth Commercial Sales Milestone [Member] Fourth Commercial Sales Milestone Amounts accrued for property and equipment Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Weighted average remaining contractual term, other than options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Unrealized Loss and Fair Values in a Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Issuance costs related to the sale of future royalties Advance Future Royalties, Issuance Costs Advance Future Royalties, Issuance Costs Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Schedule of Milestones Achieved Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount License Agreement, Centessa Pharmaceuticals (UK) Limited License Agreement, Centessa Pharmaceuticals (UK) Limited [Member] License Agreement, Centessa Pharmaceuticals (UK) Limited Termination Date Trading Arrangement Termination Date Description of the Business Nature of Operations [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Equity Incentive Plans Share-Based Payment Arrangement [Text Block] During 2027 Second Installment [Member] Second Installment Total transferred Asset Acquisition, Consideration Transferred Entity Address, City or Town Entity Address, City or Town Rosnilimab Rosnilimab [Member] Rosnilimab Schedule of Activity Related to Stock Option Awards Share-Based Payment Arrangement, Option, Activity [Table Text Block] TIM-3 (GSK4069889/Cobolimab) AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) [Member] AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) Total Share-Based Payment Arrangement, Expense Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Internal Internal Expenses [Member] Internal Expenses Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeitures and cancellations (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Area of leased property (sqft) Area of Real Estate Property Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Transition services revenue Transaction Service [Member] Transaction Service Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Approximate dollar value of shares purchased (in dollars per share) Treasury Stock, Value, Acquired, Cost Method Weighted-average number of shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Lease term Lessee, Operating Lease, Term of Contract Name Forgone Recovery, Individual Name 2025 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Aggregate intrinsic value, options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Amortization of issuance costs Amortization Of Advance Future Royalties Issuance Costs Amortization Of Advance Future Royalties Issuance Costs Non-cash interest expense Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total minimum payments required Lessee, Operating Lease, Liability, to be Paid Number of shares, beginning balance (in shares) Number of shares, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] External External Expenses [Member] External Expenses Third commercial sales milestone Third Commercial Sales Milestone [Member] Third Commercial Sales Milestone Balance Sheet Accounts and Supplemental Disclosures Supplemental Balance Sheet Disclosures [Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Upfront payment Collaborative Arrangement, Payment Collaborative Arrangement, Payment Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Milestones recognized through March 31, 2025 Cumulative Milestones Recognized [Member] Cumulative Milestones Recognized Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive gain Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] 12 months or greater, Gross unrealized losses Unrealized losses on available for sale investments in unrealized loss position for greater than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Agreement term following first commercial sale or expiration of the last to expire patent (in years) Revenue Recognition, Milestone Method, Commercial Sale Or Expiration Of Patents, Agreement Term Revenue Recognition, Milestone Method, Commercial Sale Or Expiration Of Patents, Agreement Term RSUs Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Accrued professional fees and other expenses Accrued Professional Fees, Current Executive Category: Executive Category [Axis] ANB101 ANB101 [Member] ANB101 First commercial sales milestone First Commercial Sales Milestone [Member] First Commercial Sales Milestone Name Awards Close in Time to MNPI Disclosures, Individual Name Non-cash interest expense and amortization of issuance costs Noncash Advance Future Royalties And Amortization Of Advance Future Royalties, Interest Expense Noncash Advance Future Royalties And Amortization Of Advance Future Royalties, Interest Expense Less than 12 months, Gross unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Purchases of investments Payments to Acquire Debt Securities, Available-for-Sale Company Selected Measure Name Company Selected Measure Name Initiated in vivo toxicology studies using good laboratory practices (GLPs) In Vivo Toxicology Studies [Member] In Vivo Toxicology Studies [Member] Collaboration Revenue [Member] Collaboration Revenue